Is InfuSystems Holdings (INFU) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
InfuSystem Holdings, Inc. (INFU) Q1 2026 Earnings Call Transcript
InfuSystem Holdings, Inc. (INFU) Q1 2026 Earnings Call Transcript
InfuSystems Holdings, Inc. (INFU) Q1 Earnings Top Estimates
InfuSystems Holdings, Inc. (INFU) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to a loss of $0.01 per share a year ago.
InfuSystem: Expecting Strong Stock Gains In 2026
My coverage for InfuSystem continues, focusing on recent developments and strategic positioning. INFU has made key operational improvements, has solid growth initiatives, and has the potential for continued strong revenue and earnings gains. InfuSystem's above-average growth has the potential to drive the stock for above-average long-term gains.
InfuSystem Holdings, Inc. (INFU) Q4 2025 Earnings Call Transcript
InfuSystem Holdings, Inc. (INFU) Q4 2025 Earnings Call Transcript
InfuSystems Holdings, Inc. (INFU) Q4 Earnings Beat Estimates
InfuSystems Holdings, Inc. (INFU) came out with quarterly earnings of $0.1 per share, beating the Zacks Consensus Estimate of $0.07 per share. This compares to earnings of $0.04 per share a year ago.
InfuSystem: Regulatory Backed Market Catalyst
InfuSystem: Regulatory Backed Market Catalyst
InfuSystem Stock: Margin Expansion And Growth Strategy To Drive Strong Gains
InfuSystem Holdings offers strong growth potential and appears attractively valued after reporting positive Q3 2025 earnings results. INFU's Patient Services segment, especially oncology and wound care, is driving revenue growth, while Device Solutions faced a temporary decline. Margin improvements, new contracts, and the Apollo acquisition are enhancing profitability and expanding INFU's market share and efficiency.
InfuSystem Set To Be A Cash Cow In 2026
InfuSystem (INFU) is prioritizing profitability and margin expansion under new CEO Carrie Lachance, shifting focus from unprofitable revenue streams. INFU's integration of Apollo Medical's billing system and new ERP is expected to drive significant operational efficiencies and margin gains in FY2026. Capital discipline enables INFU to repurchase shares and reduce debt, while growth opportunities in Wound Care and Oncology remain robust.
Wall Street Analysts Predict a 40% Upside in InfuSystems Holdings (INFU): Here's What You Should Know
The consensus price target hints at a 40% upside potential for InfuSystems Holdings (INFU). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Should Value Investors Buy InfuSystems Holdings (INFU) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
InfuSystems Holdings, Inc. (INFU) Tops Q3 Earnings Estimates
InfuSystems Holdings, Inc. (INFU) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to earnings of $0.08 per share a year ago.
